世卫组织警告:必须警惕抗菌素耐药性问题

2015-04-30 刘素云 国际在线

世界卫生组织29日在日内瓦发布的一份有关应对抗菌素耐药性的最新报告指出,目前在防止抗生素滥用、减少抗菌素耐药性蔓延方面仍存在重大差距,各国要制订全面国家计划应对这一问题。否则,一些本来已经可能治愈的感染性疾病将再度危及人类健康。所谓抗菌素耐药性,是指细菌、病毒、真菌和寄生虫等微生物对药物产生适应性,使得用于治疗相应感染的药物无法发挥效用。当微生物对多数抗菌素产生耐药性时,通常被称为“超级细菌”,将

世界卫生组织29日在日内瓦发布的一份有关应对抗菌素耐药性的最新报告指出,目前在防止抗生素滥用、减少抗菌素耐药性蔓延方面仍存在重大差距,各国要制订全面国家计划应对这一问题。否则,一些本来已经可能治愈的感染性疾病将再度危及人类健康。

所谓抗菌素耐药性,是指细菌、病毒、真菌和寄生虫等微生物对药物产生适应性,使得用于治疗相应感染的药物无法发挥效用。当微生物对多数抗菌素产生耐药性时,通常被称为“超级细菌”,将严重危及人类健康。因此,抗菌素耐药性问题引起了世卫组织的高度重视。世卫组织抗菌素耐药性问题协调员查尔斯·佩恩表示:“抗菌素和抗生素都是非常宝贵的资源,使得很多严重感染变得可以治愈。过去几十年中,它们拯救了成千上万的生命,然而我们也在为此付出代价。细菌和微生物对这些药物开始产生适应性,进而影响到药效,这就是我们所说的耐药性。”

去年,世卫组织发表了第一份关于全球抗菌素耐药性报告。今年公布的这份报告,是基于对全球133个国家的调查分析,首次收集了各国政府为应对抗菌素耐药性所采取的行动,涉及用于治疗血液感染、肺炎、结核病、疟疾和艾滋病毒等病症的抗菌素。报告指出,抗菌素使用不当很容易造成耐药性,例如当剂量低于标准或未完成规定的疗程时。另外,劣质药物以及药物使用不当也会引起耐药性的形成和传播。

世卫组织抗菌素耐药性问题协调员佩恩警告说,如果不能迅速采取措施应对这一问题,世界将迈向“后抗生素时代”,“过去几十年中已经可以治愈的常见感染和轻度创伤有可能再度成为杀手;面对各种严重疾病我们将可能又束手无策,例如血液感染、肺炎、肺结核、疟疾和艾滋病;先进治疗方法带来的益处也将失去,癌症的化疗和大手术的风险有可能变得更大。”

这份报告列举了目前存在的一系列问题。包括:

1.在参与调查的133个国家中,只有34个国家制订了应对耐药性问题的全面国家计划;

2.许多国家由于实验室能力低下,基础设施差和数据管理不佳,无法进行有效监测;

3.无处方销售抗生素和其它抗菌药物的现象依然广泛存在,同时许多国家缺乏标准治疗指南,增加了公众和医疗专业人员过度使用抗菌药物的可能性;

4.公众对此问题的认识程度低下,许多人仍相信抗生素可有效对抗病毒感染。

佩恩介绍说,世卫组织及其成员国以及合作伙伴联合制订了一份全球行动计划草案,将提交给5月举行的第68届世界卫生大会,“下个月召开的世界卫生大会将讨论这项全球性的应对抗菌素耐药性的全球行动计划草案。世卫组织是根据去年世界卫生大会的决定制订出这一计划的。该计划涵盖了我们需要遵守的一些共识,更为重要的是我们还将达成一些新的共识。”

世卫组织负责卫生安全问题的助理总干事福田敬二博士说,耐药性问题“是当今传染病领域面临的一项最大挑战。所有国家都必须尽自己的一份力量,应对这一全球威胁。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016204, encodeId=cc5d201620412, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Sep 15 08:22:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774891, encodeId=c31b1e748919a, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Sat Jun 20 02:22:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22460, encodeId=eac922460f5, content=研发新的抗菌药物迫在眉睫, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat May 02 22:39:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300781, encodeId=f2311300e81ff, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330521, encodeId=24681330521a9, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22354, encodeId=172522354f9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Apr 30 23:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2016204, encodeId=cc5d201620412, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Sep 15 08:22:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774891, encodeId=c31b1e748919a, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Sat Jun 20 02:22:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22460, encodeId=eac922460f5, content=研发新的抗菌药物迫在眉睫, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat May 02 22:39:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300781, encodeId=f2311300e81ff, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330521, encodeId=24681330521a9, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22354, encodeId=172522354f9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Apr 30 23:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2016204, encodeId=cc5d201620412, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Sep 15 08:22:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774891, encodeId=c31b1e748919a, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Sat Jun 20 02:22:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22460, encodeId=eac922460f5, content=研发新的抗菌药物迫在眉睫, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat May 02 22:39:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300781, encodeId=f2311300e81ff, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330521, encodeId=24681330521a9, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22354, encodeId=172522354f9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Apr 30 23:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
    2015-05-02 huaxipanxing

    研发新的抗菌药物迫在眉睫

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2016204, encodeId=cc5d201620412, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Sep 15 08:22:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774891, encodeId=c31b1e748919a, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Sat Jun 20 02:22:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22460, encodeId=eac922460f5, content=研发新的抗菌药物迫在眉睫, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat May 02 22:39:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300781, encodeId=f2311300e81ff, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330521, encodeId=24681330521a9, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22354, encodeId=172522354f9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Apr 30 23:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2016204, encodeId=cc5d201620412, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Sep 15 08:22:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774891, encodeId=c31b1e748919a, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Sat Jun 20 02:22:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22460, encodeId=eac922460f5, content=研发新的抗菌药物迫在眉睫, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat May 02 22:39:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300781, encodeId=f2311300e81ff, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330521, encodeId=24681330521a9, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22354, encodeId=172522354f9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Apr 30 23:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2016204, encodeId=cc5d201620412, content=<a href='/topic/show?id=7f2655e13cc' target=_blank style='color:#2F92EE;'>#抗菌素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55713, encryptionId=7f2655e13cc, topicName=抗菌素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Sep 15 08:22:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774891, encodeId=c31b1e748919a, content=<a href='/topic/show?id=e5ff55e11df' target=_blank style='color:#2F92EE;'>#抗菌素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55711, encryptionId=e5ff55e11df, topicName=抗菌素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeef38715773, createdName=xiongke023, createdTime=Sat Jun 20 02:22:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22460, encodeId=eac922460f5, content=研发新的抗菌药物迫在眉睫, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat May 02 22:39:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300781, encodeId=f2311300e81ff, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330521, encodeId=24681330521a9, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat May 02 07:22:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22354, encodeId=172522354f9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Thu Apr 30 23:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=)]
    2015-04-30 xiaoai5777

    好文章

    0